Post COVID-19 burden: focus on the short-term condition

Conflict of interest statement

Junhua Zhang and Boli Zhang are editorial board members of this journal.Xinyao Jin is an editorial office member and was excluded from the editorial process and publication decisions of this manuscript. Other authors declare no conflicts of interest.

Funding

This work was supported by the National Natural Science Foundation of China (A study on the correlation between TCM syndromes and disease outcome of COVID-19, No. 82004505); National Key Research and Development Program of China (Real-world study of traditional Chinese medicine for COVID-19, No. 2021YFC0863200).

Author contributions

Boli Zhang, Junhua Zhang, and Qingquan Liu conceived and designed the article. Bo Pang, Xinyao Jin, Zhe Chen, and Wentai Pang drafted the article. Fengwen Yang provided a critical version of the manuscript. All authors contributed to the revision of the manuscript and approved the final manuscript.

Ethical approval of studies and informed consent

Not applicable.

Acknowledgements

None.

References

[1] World Health Organization. WHO Coronavirus (COVID-19) dashboard; 2022. Available from:

[2] U.S. Food & Drug Administration. Coronavirus (COVID-19) |Drugs; 2022. Available from:

[3] COVID19 Vaccine Tracker Team. 11 vaccines granted emergency use listing (EUL) by WHO; 2022. Available from:

[4] Huang YF, Bai C, He F, et al. Review on the potential action mechanisms of Chinese medicines in treating Coronavirus Disease 2019 (COVID-19). Pharmacol Res. 2020;158:104939.

[5] Crook H, Raza S, Nowell J, et al.Long COVID—mechanisms, risk factors, and management. BMJ. 2021;374:n1944.

[6] Centers for Disease Control and Prevention. Long COVID or Post-COVID Condition; 2022. Available from:

[7] Al-Aly Z, Bowe B, Xie Y.Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022;28(7):1461-1467.

[8] Perego E, Callard F, Stras L, et al.Why the patient-made term “long Covid” is needed. Wellcome Open Res. 2020;5(224):224224.

[9] Greenhalgh T, Knight M, A’Court C, et al. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026.

[10] Nath A.Long-haul COVID. Neurology. 2020;95(13):559-560.

[11] Baig AM.Chronic COVID syndrome: need for an appropriate medical terminology for long-COVID and COVID long-haulers. [J] Med Virol. 2021;93(5):2555-2556.

[12] Datta SD, Talwar A, Lee JT.A proposed framework and timeline of the spectrum of disease due to SARS-CoV-2 infection: illness beyond acute infection and public health implications. JAMA. 2020;324(22):2251-2252.

[13] National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: managing the long-term effects of COVID-19. Available from:

[14] Brodin P.Immune determinants of COVID-19 disease presentation and severity. Nat Med. 2021;27(1):28-33.

[15] Nalbandian A, Sehgal K, Gupta A, et al.Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601-615.

[16] National Institutes of Health. NIH launches new initiative to study “Long COVID”; 2022. Available from:

[17] Fernández-de-Las-Peñas C, Palacios-Ceña D, Gó-Mayordomo V, et al. Defining post-COVID symptoms (post-acute COVID, long COVID, persistent post-COVID): an integrative classification. Int J Environ Res Public Health. 2021;18(5):2621.

[18] Al-Aly Z, Xie Y, Bowe B.High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021;594(7862):259-264.

[19] Centers for Diseases Control and Prevention. Post-COVID Condition; 2022. Available from: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html.

[20] World Health Organization. A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October2021; 2022. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1.

[21] Yelin D, Moschopoulos CD, Margalit I, et al.ESCMID rapid guidelines for assessment and management of long COVID. Clin Microbiol Infect. 2022;28(7):955-972.

[22] Osikomaiya B, Erinoso O, Wright KO, et al.“Long COVID”: persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria. BMC Infect Dis. 2021;21(1):304.

[23] Sudre CH, Murray B, Varsavsky T, et al.Attributes and predictors of long COVID. Nat Med. 2021;27(4):626-631.

[24] Mahmud R, Rahman MM, Rassel MA, et al.Post-COVID-19 syndrome among symptomatic COVID-19 patients: a prospective cohort study in a tertiary care center of Bangladesh. PLoS One. 2021;16(4):e0249644.

[25] Chopra V, Flanders SA, O’Malley M, et al. Sixty-day outcomes among patients hospitalized with COVID-19. Ann Intern Med. 2021;174(4):576-578.

[26] Venturelli S, Benatti SV, Casati M, et al.Surviving COVID-19 in Bergamo province: a post-acute outpatient re-evaluation. Epidemiol Infect. 2021;149:e32.

[27] Taquet M, Luciano S, Geddes JR, et al.Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA. Lancet Psychiatry. 2021;8(2):130-140.

[28] Moreno-Pérez O, Merino E, Leon-Ramirez JM, et al.Post-acute COVID-19 syndrome. Incidence and risk factors: a mediterranean cohort study. [J] Infect. 2021;82(3):378-383.

[29] Goërtz YMJ, Van Herck M, Delbressine JM, et al.Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. 2020;6(4):00542-02020.

[30] Xiong Q, Xu M, Li J, et al.Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study. Clin Microbiol Infect. 2021;27(1):89-95.

[31] Morin L, Savale L, et al.; Writing Committee for the COMEBAC Study Group. Four-month clinical status of a cohort of patients after hospitalization for COVID-19. JAMA. 2021;325(15):1525-1534.

[32] Huang L, Li X, Gu X, et al.Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. Lancet Respir Med. 2022;10(9):863-876.

[33] Fernández-de-Las-Peñas C, Palacios-Ceña D, Gómez-Mayordomo V, et al. Prevalence of post-COVID-19 symptoms in hospitalized and non-hospitalized COVID-19 survivors: a systematic review and meta-analysis. Eur [J] Intern Med. 2021;92:55-70.

[34] Chen C, Haupert SR, Zimmermann L, et al.Global prevalence of post COVID-19 condition or long COVID: a meta-analysis and systematic review. J Infect Dis 2022; published online Apr 16.

[35] Wolter N, Jassat W, Walaza S, et al.Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet. 2022;399(10323):437-446.

[36] Office for National Statistics. Self-reported long COVID after infection with the Omicron variant in the UK: 6 May2022; 2022. Available from: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionanddiseases/bulletins/selfreportedlongcovidafterinfectionwiththeomicronvariant/6may2022.

[37] Brodin P, Casari G, Townsend L, et al.Studying severe long COVID to understand post-infectious disorders beyond COVID-19. Nat Med. 2022;28(5):879-882.

[38] Iacobucci G.Long COVID: “Holistic” approach is best, given range of symptoms, say researchers. BMJ. 2022;376:o336.

[39] National Health Commission of China. Notice on the issuance of COVID-19 Diagnosis and Treatment Protocol (Trial Version 9); 2022. Available from:

[40] China Association of Chinese Medicine. Guidelines for rehabilitation of novel coronavirus pneumonia during the recovery phase of Chinese and Western medicine. Tianjin [J] Tradit Chin Med. 2020;37(05):484-489.

[41] Central People’s Government of the People’s Republic of China. Notice on the issuance of TCM Rehabilitation Guidance and Suggestions for COVID-19 Recovery (Trial); 2020. Available from:

[42] National Health Commission of China. Notification on the issuance of rehabilitation programs for major functional disorders of discharged COVID-19 patients; 2020. Available from:

[43] Traditional Chinese medicine expert group on prevention and treatment of COVID-19 in Tianjin. Rehabilitation program of coronavirus disease 2019 in Tianjin during rehabilitation period (Trial). Tianjin J Tradit Chin Med. 2022;39(3):275-277.

[44] Health Commission of Hebei Province. Hebei Administration of Traditional Chinese Medicine, Rehabilitation Guidelines of Integrated Medicine for COVID-19 patients in Hebei Province; 2021. Available from:

[45] Pang W, Yang F, Zhao Y, et al.Qingjin Yiqi granules for post-COVID-19 condition: a randomized clinical trial. [J] Evid Based Med. 2022;15(1):30-38.

[46] Chen Y, Liu C, Wang T, et al.Efficacy and safety of Bufei Huoxue capsules in the management of convalescent patients with COVID-19 infection: a multicentre, double-blind, and randomised controlled trial. [J] Ethnopharmacol. 2022;284:114830.

[47] Li L, An XD, Zhang Q, et al.Shumian capsule improves symptoms of sleep mood disorder in convalescent patients of Corona Virus Disease 2019. [J] Tradit Chin Med. 2021;41(6):974-981.

[48] Li L, Gou CY, Li XM, et al.Effects of Chinese medicine on symptoms, syndrome evolution, and lung inflammation absorption in COVID-19 convalescent patients during 84-day follow-up after hospital discharge: a prospective cohort and nested case-control study. Chin [J] Integr Med. 2021;27(4):245-225.